Description | The antibody CV3-13 binds to SARS-CoV-2 spike protein. It binds from a distinct angle of approach to an N-terminal domain (NTD) epitope. The antibody does not alter the replication dynamics of SARS-CoV-2 in K18-hACE2 mice, but its Fc enhanced version significantly delays virus spread, neuroinvasion, and death in prophylactic settings. It is a non-nAb with potent Fc-mediated effector functions. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | SARS-CoV-2 |
Epitope | N-terminal domain (NTD) |
Isotype | IgG1 |
Expression Species | HEK293F or CHO cell line |
Conjugation | Unconjugated |
Purity | >95% |
Endotoxin | <1 EU/mg |
Form | Liquid |
Purification | Protein A purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
Application | ELISA |
Application Notes | Recombinant SARS-CoV-2 S-6P, or BSA as a negative control, were prepared in PBS and were adsorbed to plates overnight at 4°C. Coated wells were subsequently blocked with blocking buffer for 1 h at room temperature. Wells were then washed four times with washing buffer. mAbs (50 ng/mL) were prepared in a diluted solution of blocking buffer and incubated in the coated wells for 90 min at room temperature. Plates were washed four times with washing buffer followed by incubation with HRP-conjugated anti-Human IgG secondary Abs for 1 h at room temperature, followed by four washes. HRP enzyme activity was determined after the addition of 40 μL of a 1:1 mix of Western Lightning oxidizing and luminol reagents. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Western Blot Protocol |
Target | SARS-CoV-2 |
Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
Research Area | Coronavirus Disease 2019 |
Related Disease | Coronavirus Disease 2019 |